Items Tagged ‘ET’

November 22nd, 2017

Incyte Announces Initiation of Clinical Trial Evaluating Jakafi® for the Treatment of Essential Thrombocythemia

By

Incyte Corporation announced that the first patient has been treated in the RESET pivotal trial evaluating Jakafi®  (ruxolitinib) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant of hydroxyurea (HU). “We are pleased to treat the first patient in our pivotal trial evaluating ruxolitinib as a […]

View full entry

Tags: essential thrombocythemia, ET, Incyte Corporation, jakafi, Myeloproliferative Neoplasms MPN, News, RESET Clinical Trial, ruxolitinib


December 16th, 2016

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia

By

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the American Society of Hematology. Myeloproliferative neoplasms (MPNs) are a related group of blood cancers. In these disorders, the bone marrow cells […]

View full entry

Tags: 2016, American Society of Hematology, ASH, essential thrombocythemia, ET, hydroxyurea, Interferon, interferon alpha-2a, MPD-RC 112 trial, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN


October 10th, 2016

Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life

By

According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health of patients even a year before their diagnosis. Myeloproliferative neoplasms (MPN) are a related group of blood cancers. In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. The three […]

View full entry

Tags: essential thrombocythemia, ET, mpn, Myeloproliferative Neoplasms MPN, News, PMF, polycythemia vera, primary myelofibrosis, PV


May 18th, 2016

Addition of Radiation Improves Survival in High-Risk Prostate Cancer

By

The addition of radiation therapy to androgen-deprivation therapy among men with prostate cancer who are at a high risk of a cancer recurrence significantly improves long-term survival. These results were recently published in the journal of European Urology. Prostate cancer is the most frequently diagnosed cancer in men aside from skin cancer. An estimated 220,800 […]

View full entry

Tags: adt, androgen deprivation therapy, endrocrine treatment, ET, News, Prostate Cancer, radiation therapy